Podcast + Q&A: Device-Makers Shouldn't Ignore Pharma Quality Metrics Initiative, Attorney Says
This article was originally published in The Gray Sheet
In a Dec. 9 podcast interview at the Food and Drug Law Institute Enforcement, Litigation and Compliance meeting in Washington, D.C., Alston & Bird partner Cathy Burgess discussed how the FDA’s quality metrics initiative for pharmaceutical companies may also impact expectations for device manufacturers down the line.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.